Last reviewed · How we verify
NCT06666790
DermaSensor Postmarket Surveillance Study
NA trial testing Scan with elastic scattering spectroscopy device to assess risk of malignancy in Melanoma, Skin in 396 participants. Currently enrolling.
11 April 2027
Quick facts
| Lead sponsor | DermaSensor, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | screening |
| Enrollment | 396 |
| Start date | 8 October 2024 |
| Primary completion | 11 April 2027 |
| Estimated completion | 10 September 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Scan with elastic scattering spectroscopy device to assess risk of malignancy
Conditions studied
- Melanoma, Skin — all drugs for Melanoma, Skin →
Sponsor
DermaSensor, Inc.
Who can join
40 and older, any sex, with Melanoma, Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06666790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma, Skin
Currently open trials in the same condition.
- NCT06754904 — Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the In · NA · recruiting
- NCT06809491 — One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy · active not recruiting
- NCT06605417 — Understanding the Transition from Normal Melanocytes to Nevus to Melanoma · recruiting
Other DermaSensor, Inc. trials
Trials by the same sponsor.
- NCT06690086 — DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of S · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06666790 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DermaSensor, Inc.
- Last refreshed: 31 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06666790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing